

# pUNO1-mSTING-Gt

Expression vector containing Goldenticket (Gt) isoform mouse STING (I199N) open reading frame

Catalog code: puno1-msting-gt

[www.invivogen.com/hsting-gt](http://www.invivogen.com/hsting-gt)

For research use only

Version 19K10-MM

## PRODUCT INFORMATION

### Contents

- 20 µg of lyophilized plasmid DNA
- 2 x 1 ml blasticidin at 10 mg/ml

### Storage and Stability

- Product is shipped at room temperature.
- Lyophilized DNA should be stored at -20°C.
- Resuspended DNA should be stored at -20°C and is stable at least for 1 year.
- Store blasticidin at 4°C or -20°C.\*

\*The expiry date is specified on the product label.

### Quality control

- Plasmid construct has been confirmed by restriction analysis and full-length open reading frame (ORF) sequencing.
- Plasmid DNA was purified by ion exchange chromatography.

## GENERAL PRODUCT USE

- **Subclone gene into another vector.** Two unique restriction sites flank the gene, allowing convenient excision. The 5' site is BspEI which is compatible with AgeI, XmaI, NgoMIV and SgrAI. The 3' site is NheI which is compatible with XbaI, SpeI, and AvrII.
- **Stable gene expression in mammalian cells.** pUNO1 plasmids can be used directly in transfection experiments both *in vitro* and *in vivo*. pUNO1 plasmids contain the blasticidin-resistance gene (*bsr*) driven by the CMV promoter/enhancer in tandem with the bacterial EM7 promoter. This allows the amplification of the plasmid in *E. coli*, as well as the selection of stable clones in mammalian cells using the same selective antibiotic. pUNO1 allows high levels of expression and secretion of the gene product.

## METHODS

### Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile water. Store resuspended plasmid at -20°C.

### Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5α.

### Blasticidin usage

Blasticidin should be used at 25-100 µg/ml in bacteria and 1-30 µg/ml in mammalian cells. Blasticidin is supplied at 10 mg/ml in HEPES buffer.

## PLASMID FEATURES

- **Bsr (blasticidin resistance gene):** The *bsr* gene from *Bacillus cereus* encodes a deaminase that confers resistance to the antibiotic blasticidin. The *bsr* gene is driven by the CMV promoter/enhancer in tandem with the bacterial EM7 promoter. Therefore, blasticidin can be used to select stable mammalian cells transfectants and *E. coli* transformants.
- **CMV promoter & enhancer** drives the expression of the blasticidin resistance in mammalian cells.

### • Mouse STING-Gt

**ORF size:** 1137 bp

**Cloning fragment size:** 1148 bp

STING (stimulator of interferon genes; also known as TMEM173, MITA, MPYS, and ERIS) is essential for the IFN response to microbial or self-DNA, and acts as a direct sensor of cyclic dinucleotides (CDNs). CDNs are important messengers in bacteria, affecting numerous responses of the prokaryotic cell, but also in mammalian cells, acting as agonists of the innate immune response. Studies have revealed that STING variation can affect CDN recognition and signal transduction. The I199N mutation carried by the *Goldenticket* (Gt) mouse strain fails to produce type I IFNs upon bacterial infection or in response to c-di-GMP, a bacterial CDN<sup>1</sup>. The I199N missense mutation lies in exon 6 of the mouse STING gene and results in a null-phenotype with no detectable STING activity.

• **EF-1α/HTLV hybrid promoter** is a composite promoter comprised of the Elongation Factor-1α (EF-1α) core promoter<sup>2</sup> and the 5' untranslated region of the Human T-Cell Leukemia Virus (HTLV). EF-1α utilizes a type 2 promoter that encodes for a «house keeping» gene. It is expressed at high levels in all cell cycles and lower levels during G0 phase. The promoter is also non-tissue specific; it is highly expressed in all cell types. The R segment and part of the U5 sequence (R-U5') of the HTLV Type 1 Long Terminal Repeat<sup>3</sup> has been coupled to the EF-1α promoter to enhance stability of DNA and RNA. This modification not only increases steady state transcription, but also significantly increases translation efficiency possibly through mRNA stabilization.

• **SV40 pAn:** The Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions, resulting in high levels of steady-state mRNA<sup>4</sup>.

• **pMB1 ori** is a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

• **Human beta-Globin polyA** is a strong polyadenylation (pAn) signal placed downstream of *bsr*. The use of beta-globin pAn minimizes interference<sup>5</sup> and possible recombination events with the SV40 polyadenylation signal.

1. Sauer JD. *et al.*, 2011. The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the *in vivo* interferon response to *Listeria monocytogenes* and cyclic dinucleotides. *Infect Immun* 79(2):688-94. 2. Kim D. *et al.*, 1990. Use of the human elongation factor 1α promoter as a versatile and efficient expression system. *Gene* 91(2):217-23. 3. Takebe Y. *et al.*, 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. *Mol Cell Biol*. 8(1):466-72. 4. Carswell S. & Alwine J., 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. *Mol Cell Biol*. 9(10):4248-58. 5. Yu J. & Russell J., 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human β-Globin mRNA. *Mol Cell Biol*. 21(17):5879-88.

## RELATED PRODUCTS

| Product                        | Description                                      | Cat. Code            |
|--------------------------------|--|----------------------|
| Blasticidin<br>ChemiComp GT116 | Selection antibiotic<br>Competent <i>E. coli</i> | ant-bl-1<br>gt116-11 |

### TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873


InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: [info@invivogen.com](mailto:info@invivogen.com)

 **InvivoGen**  
[www.invivogen.com](http://www.invivogen.com)



125

**PvuI (7)**  
**SgfI (6)** MfeI (82) EcoNI (96)  
1 GGATCTGCGATCGCTCCGGTCCCGTCAGTGGGCAGAGCGACATCGCCACAGTCCCCGAGAAGTTGGGGGAGGGGTCCGGCAATTGAACGGGTGCCTA

101 GAGAAGGTGGCGCGGGTAAACTGGGAAAGTATGTCGTGTACTGGCTCCGCCCTTTTCCCGAGGGTGGGGGAGAACCCTATATAAGTGCAGTAGTCGCC

**HindIII (245)** **Bsu36I (291)**  
**Psp1406I (203)** **PvuII (239)** EcoNI (287)  
201 GTGAACGTTCTTTTTCGCAACGGGTTTCCGCCAGAACACAGCTGAAGCTTCGAGGGCTCGCATCTCTCTTCCACGCCCGCCGCCCTACCTGAGGGC

301 GCCATCCACGCCGGTTGAGTCGCGTCTGCCGCCTCCCGCTGTGGTGCCTCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACC

**NgoMI (441)** **NaeI (441)**  
401 GGGCCTTTGTCCGGCGCTCCCTTGAGCGCTACCTAGACTCAGCCGGCTCTCCACGCTTTCCTGACCTGCTTGTCAACTCTACGCTTTTGTTTCGTTT

**AgeI (552)**  
501 TCTGTTCTGGCCGTTACAGATCCAAGCTGTGACCGCCGCTACCTGAGATCACCGTCCAGTGCATGCTCAACTGCATCCAGCCATCCACGGCC  
1 M P Y S N L H P A I P R P

**BsrBI (609)** **BstEII (604)** **MscI (641)** **BamHI (672)**  
601 CAGAGGTACCCTCCAAATATGTAGCCCTCATCTTTCTGGTGGCAGCCTGATGATCCTTTGGGTGGCAAAGGATCCACCAAATCACACTCTGAAGTAC  
13 R G H R S K Y V A L I F L V A S L M I L W V A K D P P N H T L K Y

**Asp718 (788)** **Acc65I (788)**  
701 CTAGCACTTACCTAGCTCGCACGAACTTGGACTACTGTTGAAAACCTCTGCTGTCTGGCTGAAGAGCTGTGCCATGTCCAGTCCAGTACCAGGGCA  
47 L A L H L A S H E L G L L L K N L C C L A E E L C H V Q S R Y Q G

**BssHII (816)**  
801 GCTACTGGAAGGCTGTGCGCGCTGCTGGGATGCCCATCCACTGTATGGCTATGATTCTACTATCGTCTTATTCTATTCTCCAAAACACTGCTGA  
80 S Y W K A V R A C L G C P I H C M A M I L L S S Y F Y F L Q N T A D

**PstI (992)**  
901 CATATACCTCAGTTGGATGTTTGGCCTTCTGGTCTCTATAAGTCCCTAAGCATGCTCCTGGCCTTCCAGAGCTTACTCCAGCGGAAGTCTCTGCAGTC  
113 I Y L S W M F G L L V L Y K S L S M L L G L Q S L T P A E V S A V

**BamHI (1091)**  
1001 TGTGAAGAAAAGTAAATGTTGCCACGGGCTGGCTGGTCACTACATTGGTACTTGGGTTGATCTTACCAGGGCTCCAGCCCGGATCCGAA  
147 C E E K K L N V A H G L A W S Y Y I G Y L R L I L P G L Q A R I R

**BsrGI (1151)** **BpuAI (1145)** **BbsI (1145)**  
1101 TGTTCAATCAGTACATAACAACATGCTCAGTGGTGCAGGGAGCCGAAGACTGTACAACCTCTTCCATTGGACTGTGGGGTGCCTGACAACTGAGTGT  
180 M F N Q L H N N M L S G A G S R R L Y N L F P L D C G V P D N L S V  
1201 AGTTGACCCCAACATTGATTCGAGATATGCTGCCAGCAAAAACATCGACCGTGGCATCAAGAATCGGGTTTATTCCAACAGCGTCTACGAGATT  
213 V D P N I R F R D M L P Q Q N I D R A G I K N R V Y S N S V E I  
1301 CTGAGAACGGACAGCCAGCAGGCGTCTGTATCCTGGAGTACGCCACCCCTTGCAGACCCTGTTGCCATGTCCAGGATGCCAAAAGTGGCTTCAGTC  
247 L E N G Q P A G V C I L E Y A T P L Q T L F A M S Q D A K A G F S  
1401 GGGAGGATCGGCTTGGAGCAGGCTAACTCTTCTGCCGACACTTGGAGAACTCTGGAAAGATGTCGCCGAGTCTCGAAATAACTGCCGCCTCATTGTCTA  
280 R E D R L E Q A K L F C R T L E E I L E D V P E S R N N C R L I V Y

**BstEII (1578)**  
1501 CCAAGAACCACAGACGGAAACAGTTTCTCACTGTCTCAGGAGGTGCTCCGGCACCATTGTCAGGAAGAAAAGGAGGTTACCATGAATGCCCCCATG  
313 Q E P T D G N S F S L S Q E V L R H I R Q E E K E E V T M N A P M  
1601 ACCTCAGTGGCACCTCTCCCTCCGTAAGTCTCCCAAGAGCAAGACTCCTCATCAGTGGTATGGATCAGCCTCTCCCACTCCGCACTGACCTCATCTGA  
347 T S V A P P S V L S Q E P R L L I S G M D Q P L P L R T D L I •

**MscI (1706)** **NheI (1700)**  
1701 GCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACCTAGAATGCAGTGAATAAATGCTTTATTTGTGAAATTTGTGATGCTA

**HpaI (1838)** **MfeI (1849)**  
1801 TTGCTTTATTTGTAACCATTAAGTGAATAAACAAGTAAACAACAACATTCATTCTTTATGTTTCAGGTTCCAGGGGAGGTGTGGGAGGTTTT

**EcoRI (1934)**  
1901 TTAAGCAAGTAAACCTCTACAAATGTGGTATGGAATCTAAAATACAGCATAGCAAACTTTAACCTCCAATCAAGCCTCTACTTGAATCCTTTTCT  
2001 GAGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTCTTTCATGGAGTTAAGATATAGTGTATTTT

**SspI (2173)** **SwaI (2187)**  
2101 CCCAAGTTTGAAGTACTCTTCACTTTCTTTATGTTTTAAATGCACTGACCTCCACATTCCTTTTATAGTAAATATTCAGAAATAATTTAAATACATC

**EcoO109I (2248)**  
2201 ATTGCAATGAAAATAAATGTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAATATCCCCAGTTTAGTAGTTGGAAGTACAGGAAACAAAGGA

2301 ACCTTTAATAGAAAATGGACAGCAAGAAAGCGAGCTTCTAGCTTTAGTCTCTGGTGTACTTGGGGGATGAGTTCCTCAATGGTGGTTTTGACCGCTT  
144 • N R T Y K L P I L E E I T T K V L K

**SacI (2448)** **Ecl136II (2448)** **BstXI (2477)**  
2401 GCCATTCTCAATGAGCACAAGCAGTCCAGGAGCATAGTCAGAGATGAGCTCTGACATGCCACAGGGGCTGACCACCTGATGGATCTGTCCACC  
122 G N M E I L V F C D P A Y D S I L E R C M G C P S V V R I S R D V  
2501 TCATCAGAGTAGGGTGCCTGACAGCCACAATGGTGTCAAAGTCTTCTGCCGCTTGTCTCACAGCAGACCAATGGCAATGGCTTACGACAGACAGTGA  
88 E D S Y P H R V A V I T D F D K Q G N S V A S G I A I A E A C V T V

**StuI (2612)**  
2601 CCCTGCCAATGTAGGCTCAATGTGGACAGCAGAGATGATCTCCCGCTTGGTCTGATGGCCGCCCGACATGGTCTTGTGCTCATAGAGCAT  
55 R G I Y A E I H V A S I E G T K T R I A A G V H H K N D E Y L M

**BspHI (2762)**  
 BpuAI (2758)  
 BbsI (2758)  
**XmnI (2754)**

2701 GGTGATCTTCTCAGTGGCGACCTCCACCAGCTCCAGATCCTGCTGAGAGATGTTGAAGTCTTCATGATGGCCCTCTATAGTGAGTCGTATTATACTAT  
 22 T I K E T A V E V L E L D Q Q S I N F T K M

SacI (2877)  
 Ecl136II (2877)

2801 GCCGATATACTATGCCGATGATTAATTGTCAAACACAGCGTGGATGGCGTCTCCAGCTTATCTGACGGTCACTAAACGAGCTCTGCTTATATAGACCTCC

**SpeI (2975)**

2901 CACCGTACACGCTACCGCCATTTCGCTCAATGGGGCGGAGTTGTTACGACATTTTGAAAGTCCCGTTGATTTACTAGTCAAAACAACTCCCATTGA  
 3001 CGTCAATGGGGTGGAGACTTGAAATCCCCGTGAGTCAAACCGCTATCCACGCCATTGATGTACTGCCAAAACCGCATCATCATGGTAATAGCGATGAC

**SnaBI (3103)**

3101 TAATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAAGTCTGACTGGGCATAATGCCAGCGGGCCATTACCGTCATTGACGTCAATAGGGGGC

**NdeI (3208)**

3201 GTACTTGGCATATGATACACTTGTACTGCAAGTGGGCAGTTTACCGTAAATACTCCACCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTA

PacI (3394)  
 PstI (3387)  
**SdaI (3386)**  
**SbfI (3386)**

3301 TGGAAACATACGTCATTATTGACGTCAATGGGCGGGGTCGTTGGCGGTCAGCCAGCGGGCCATTTACCGTAAGTTATGTAACGCTGCAGGTTAATT

**PciI (3404)**  
**BspLU11I (3404)**

3401 AAGAACATGTGAGCAAAGGCCAGCAAAGGCCAGGAACCGTAAAAGGCCGCTTGTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACA  
 3501 AAAATCGACGCTCAAGTCAGAGGTGGCAAACCCGACGAGCTATAAAGATACCAGGCGTTTCCCCTGGAAGCTCCCTCGTGCCTCTCTGTTCGAC  
 3601 CCGTGGCGTTACCGGATACCTGTCGCTTCTCCCTTCGGGAAGCGTGGCGCTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTT

**ApaLI (3718)**

3701 CGCTCCAAGCTGGGCTGTGTGCACGAACCCCCGTTAGCCGACCGCTGCGCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACT  
 3801 TATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACAC  
 3901 TAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGAAAAAGAGTTGGTAGCTTTGATCCGGCAAACAAACCACCGCTGGTAGC  
 4001 GGTGGTTTTTTTGTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTCTACGGGGTCTGACGCTCAGTGGAAACG

**EagI (4154)**  
 PacI (4134) SmaI (4143) **NotI (4153)**

4101 AAAACTCACGTTAAGGGATTTTGGTATGGCTAGTTAATTAACATTTAAATCAGCGGCCGAATAAAATATCTTTATTTTATTACATCTGTGTGTTGGT  
 4201 TTTTGTGTGAATCGTAACTAACATACGCTCTCCATCAAACAAACGAAACAAACAACTAGCAAATAGGCTGTCCCAAGTCAAGTGCAGGTGCCA  
 4301 GAACATTTCTCTATCGAA